Detecting KRAS mutations in peripheral blood of colorectal cancer patients by peptide nucleic acid clamp PCR

Experimental and Therapeutic Medicine

Volumn 4, Issue 5, 2012, Pages 790-794

  Miyano, Shozo ^a   Hanazawa, Kisaburo ^a   Kitabatake, Toshiaki ^a   Fujisawa, Minoru ^a   Kojima, Kuniaki ^a  

^a JUNTENDO UNIVERSITY NERIMA HOSPITAL   (Japan)

Author keywords

Colorectal cancer; KRAS mutation; Peptide nucleic acid; Plasma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FORMALDEHYDE; K RAS PROTEIN; MONOCLONAL ANTIBODY; PARAFFIN; PEPTIDE NUCLEIC ACID;

ACCURACY; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CELL MUTANT; CLINICAL ARTICLE; CODON; COLORECTAL CANCER; FEMALE; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOLECULARLY TARGETED THERAPY; POINT MUTATION; POLYMERASE CHAIN REACTION; POSTOPERATIVE COMPLICATION; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

EID: 84866361656     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.694     Document Type: Article

References (20)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Wolpin BM and Mayer RJ: Systemic treatment of colorectal cancer. Gastroenterology 134: 1296-1310, 2008.
3. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, et al: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 20: 1803-1810, 2005.
4. Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, Celik I, Schlichting M and Koralewski P: Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 22: 1535-1546, 2011.
5. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408-1417, 2009.
6. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I and Kerr D: Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 9: 489-499, 2009.
7. Bardelli A and Siena SJ: Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. Clin Oncol 28: 1254-1261, 2010.
8. Winder T and Lenz HJ: Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer. Gastroenterology 138: 2163-2176, 2010.
9. Chua W, Goldstein D, Lee CK, Dhillon H, Michael M, Mitchell P, Clarke SJ and Iacopetta B: Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. Br J Cancer 101: 998-1004, 2009.
10. Gilje B, Heikkilä R, Oltedal S, Tjensvoll K and Nordgard O: High-fidelity DNA polymerase enhances the sensitivity of a peptide nucleic acid clamp PCR assay for K-ras mutations. Mol Diagn 10: 325-331, 2008.
11. Forbes S, Clements J, Dawson E, Bamford S, Webb T, Dogan A, Flanagan A, Teague J, Wooster R, Futreal PA and Stratton MR: COSMIC 2005. Br J Cancer 94: 318-322, 2006.
12. Poehlmann A, Kuester D, Meyer F, Lippert H, Roessner A and Schneider-Stock R: K-ras mutation detection in colorectal cancer using the Pyrosequencing technique. Pathol Res Pract 203: 489-497, 2007.
13. Raponi M, Winkler H and Dracopoli NC: KRAS mutations predict response to EGFR inhibitors. Curr Opin Pharmacol 8: 413-418, 2008.
14. Saif MW and Shah M: K-ras mutations in colorectal cancer: a practice changing discovery. Clin Adv Hematol Oncol 7: 45-53, 2009.
15. Klein CA: Parallel progression of primary tumours and metastases. Nat Rev Cancer 9: 302-312, 2009.
16. Knijn N, Mekenkamp LJ, Klomp M, Vink-Börger ME, Tol J, Teerenstra S, Meijer JW, Tebar M, Riemersma S, van Krieken JH, et al: KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 104: 1020-1026, 2011.
17. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM and Bos JL: Genetic alterations during colorectal-tumor development. N Engl J Med 319: 525-532, 1988.
18. Wang JY, Yeh CS, Chen YF, Wu CH, Hsieh JS, Huang TJ, Huang SY and Lin SR: Development and evaluation of a colorimetric membrane-array method for the detection of circulating tumor cells in the peripheral blood of Taiwanese patients with colorectal cancer. Int J Mol Med 17: 737-747, 2006.
19. Lindforss U, Zetterquist H, Papadogiannakis N and Olivecrona H: Persistence of K-ras mutations in plasma after colorectal tumor resection. Anticancer Res 25: 657-661, 2005.
20. Beau-Faller M, Legrain M, Voegeli AC, Guérin E, Lavaux T, Ruppert AM, Neuville A, Massard G, Wihlm JM, Quoix E, et al: Detection of K-ras mutations in tumor samples of patients with non-small cell lung cancer using PNA-mediated PCR clamping. Br J Cancer 100: 985-992, 2009.